Tenon Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Tenon Medical (NASDAQ:TNON) announced that Nasdaq has confirmed the company has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). The company had previously fallen below the threshold for 30 consecutive business days, triggering a Nasdaq notification on February 25, 2026.

According to Tenon Medical, a 1-for-35 reverse stock split effective August 10, 2026 lifted the closing bid price to at least $1.00 for 10 consecutive business days through August 21, 2026, restoring compliance as of August 24, 2026. Tenon’s common stock continues to trade on the Nasdaq Capital Market under the symbol TNON.

Positive

• Regained Nasdaq bid price compliance after 10 days at or above $1.00
• 1-for-35 reverse stock split effective August 10, 2026 completed
• Nasdaq Capital Market listing maintained under symbol TNON

Negative

• None.

News Explained

The August 10, 2026 1-for-35 reverse split consolidated Tenon’s shares and proportionally raised the per-share price without changing company value by the split itself; Nasdaq’s notice confirms the resulting bid-price deficiency is now closed.

Market Context

Tenon's FDA clearance was followed by a -10.34% 24-hour reaction, showing that favorable regulatory ...

Analysis

Tenon's FDA clearance was followed by a -10.34% 24-hour reaction, showing that favorable regulatory news previously diverged from market response. This compliance update removes the stated listing issue, while the active shelf remains a financing risk.

Key Figures

Nasdaq listing rule: 5550(a)(2) Minimum bid price: $1.00 per share Prior deficient period: 30 consecutive business days +3 more

6 metrics

Nasdaq listing rule 5550(a)(2) Minimum bid price requirement

Minimum bid price $1.00 per share Nasdaq Bid Price Rule threshold

Prior deficient period 30 consecutive business days Closing bid price below Nasdaq's minimum

Reverse stock split 1-for-35 Effective August 10, 2026

Compliance period 10 consecutive business days August 10, 2026 through August 21, 2026

Compliance notice date August 24, 2026 Nasdaq notified Tenon that the matter was closed

Historical Context

5 past events · Latest: Aug 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 13	2Q26 earnings report	Negative	-13.4%	Revenue and margin growth accompanied a larger net loss and declining cash balance.
Aug 06	Reverse stock split	Negative	-12.4%	The 1-for-35 split targeted Nasdaq's $1.00 minimum closing-price requirement.
Jul 30	Earnings date notice	Neutral	+1.6%	The company scheduled second-quarter results and a subsequent analyst conference call.
Jul 20	Nasdaq compliance update	Positive	+3.8%	Nasdaq confirmed regained stockholders' equity compliance after a $4.2 million offering.
Jul 02	FDA clearance	Positive	-10.3%	FDA clearance covered instrument upgrades and reusable-tool reclassification.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent responses were mixed: the July compliance update aligned positively, while FDA clearance and earnings news were followed by declines.

Key Terms

minimum bid price requirement, closing bid price, reverse stock split

3 terms

minimum bid price requirement regulatory

"regained compliance with the minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

closing bid price financial

"the closing bid price of the Company's common stock"

The closing bid price is the last price that a buyer was willing to pay for a security at the end of the trading day. It reflects the final visible demand for the stock — like the last offer someone makes for a used car before a yard closes — and helps investors gauge market interest, set valuations, and mark portfolios to market for that day.

reverse stock split financial

"Following the Company's previously announced 1-for-35 reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS GATOS, CA / ACCESS Newswire / August 24, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").

On February 25, 2026, the Company received a letter from the Listing Qualifications staff of Nasdaq (the "Staff") notifying it that, for the prior 30 consecutive business days, the closing bid price of the Company's common stock had been below the $1.00 per share minimum required under the Bid Price Rule.

Following the Company's previously announced 1-for-35 reverse stock split, effective August 10, 2026, the closing bid price of the Company's common stock was $1.00 per share or greater for each of the 10 consecutive business days from August 10, 2026 through August 21, 2026. On August 24, 2026, the Staff notified the Company in writing that the Company has regained compliance with the Bid Price Rule and that this matter is now closed.

The Company's common stock continues to trade on the Nasdaq Capital Market under the symbol "TNON."

About Tenon Medical, Inc.

Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran^™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+^® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct.

For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.

The Tenon Medical logo shown above, and Catamaran^®, PiSIF^®, CAT PiSIF^®, ETAD^®, Posterior Inferior Sacroiliac Fusion^®, CAT SIJ Fusion System^®, Catamaran SIJ Fusion System^®, Catamaran Inferior Posterior Fusion System^®, Catamaran Transfixation Fusion System^®, Catamaran Transfixation Fusion Device^®, SImmetry^® are registered trademarks of Tenon Medical, Inc. MAINSAIL^™, and SImmetry+ are also trademarks of Tenon Medical, Inc.

Safe Harbor

This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements include, but are not limited to, statements regarding the Company's ability to maintain compliance with Nasdaq listing requirements and the continued listing of the Company's common stock on the Nasdaq Capital Market. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

IR Contact:

Shannon Devine
203-741-8811
MZ North America
tenon@mzgroup.us

SOURCE: Tenon Medical, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Nasdaq’s compliance notice mean for Tenon Medical (TNON) on August 24, 2026?

Nasdaq’s notice on August 24, 2026 confirmed that Tenon Medical had regained compliance with the minimum bid price rule. According to Tenon Medical, this closed the prior deficiency matter and allowed its common stock to continue trading on the Nasdaq Capital Market under the symbol TNON.

How did Tenon Medical (TNON) regain compliance with Nasdaq’s $1.00 minimum bid price rule?

Tenon Medical regained compliance by effecting a 1-for-35 reverse stock split on August 10, 2026. According to Tenon Medical, the post-split closing bid price stayed at or above $1.00 for 10 consecutive business days from August 10 through August 21, meeting Nasdaq’s criteria.

What was the issue with Tenon Medical’s (TNON) share price before the reverse stock split?

Before the reverse stock split, Tenon Medical’s stock traded below $1.00 for 30 consecutive business days. According to Tenon Medical, Nasdaq’s Listing Qualifications staff notified the company on February 25, 2026 that this price level did not satisfy the Bid Price Rule under Listing Rule 5550(a)(2).

Does Tenon Medical (TNON) remain listed on the Nasdaq Capital Market after regaining compliance?

Yes, Tenon Medical’s common stock continues to trade on the Nasdaq Capital Market under the symbol TNON. According to Tenon Medical, Nasdaq’s August 24, 2026 notice confirmed closure of the bid price deficiency, allowing the company to maintain its current listing status and ticker.

What reverse stock split ratio did Tenon Medical (TNON) use to address the Nasdaq bid price requirement?

Tenon Medical implemented a 1-for-35 reverse stock split effective August 10, 2026. According to Tenon Medical, this corporate action increased the per-share trading price, enabling the company’s closing bid price to reach at least $1.00 for 10 consecutive business days and satisfy Nasdaq’s rule.

What products and market focus does Tenon Medical (TNON) have following its Nasdaq compliance update?

Tenon Medical focuses on devices for sacroiliac (SI) joint disorders, including the Catamaran SI Joint Fusion System and SImmetry+ system. According to Tenon Medical, it targets primary SI joint procedures, revision of failed implants, and SI joint fusion adjunct to spine fusion constructs in the U.S. market.